Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)

NCT02729025 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02729025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02729025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
April 14, 2016
Completion date
April 5, 2018
Enrollment
129 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

subjects with hyperlipidemia, dyslipidemia